AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06608745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer-assisted total knee arthroplasty
Description: total knee arthroplasty performed with imageless computer-assisted surgery
Study NCT06608433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: semaglutide/Rybelsus will be administered as a single oral dose
Study NCT06608433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be administered as a single oral dose
Study NCT06607874 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional study
Study NCT06608576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face standard treatment
Description: Individualized early intervention treatment on physical therapy area as usual in the early intervention facilities once a month for two months. Instructions will be given to the parents for follow-up at home to stimulate the baby's motor development until next face-to-face session.
Study NCT06608576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telematic Support
Description: The physiotherapist in charge of the telematic sessions will review and guide in real time through WhatsApp platform, the performance and active participation of the parents in the therapeutic activities being asked to follow-up at home in the face-to-face appointment, correcting, as necessary.
Study NCT06608719 — intervention group
Intervention type: BIOLOGICAL
Intervention: The study drug is SHED-CM manufactured by U-Factor
Description: Patients diagnosed with ALS were administered SHED-CM
Study NCT06606132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person\&#39;s condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
Study NCT05135403 — intervention group
Intervention type: DEVICE
Intervention: Defibrillation
Description: External defibrillation from a wearable cardioverter defibrillator
Study NCT05070026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uni-portal VATS group
Description: patients received pulmonary lobectomy under general anesthesia by using uni-portal VATS method
Study NCT05070026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: three port VATS group
Description: patients received pulmonary lobectomy under under general anesthesia by using three port VATS method
Study NCT05606497 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid
Description: Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
Study NCT04710979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: This group will have in-person, 60 minute yoga sessions three times per week for 12 weeks. These sessions will also include a sharing circle to provide group feedback as to how the practice felt and integration into ones' daily life. There will be biweekly themes established for these sessions (i.e. common yoga poses, importance of breath) and biweekly in-person workshops will be offered. These will be specialty classes for participants to experience additional exposure to meditation and breathing. They will be a longer format so participants can delve deeper into yogic philosophy and practice. There will also be a private Facebook group for participants to connect with each other and for the research staff to maintain contact and share information with the participants (eg. weekly reminder for yoga sessions and workshops).
Study NCT05132049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5211
Description: single dose administration (DA-5211 one tablet once a day)
Study NCT05132049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5211-R1 + DA-5211-R2
Description: single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
Study NCT04433780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Description: DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
Study NCT05150093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
Study NCT06207617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement + customized healing abutment
Description: Immediate implant placement in fresh extraction molar sites + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant. no grafting material included in this arm
Study NCT06207617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement + xenogeneic bone graft material + customized healing abutment
Description: Immediate implant placement in fresh extraction molar sites + xenogenic bone graft + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
Study NCT04900220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
Study NCT06608615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm
Study NCT06608615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side.
Study NCT06607783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: TBC
Study NCT06608420 — intervention group
Intervention type: OTHER
Intervention: Gradient Boosting Survival Analysis (GBSA),
Description: It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.
Study NCT06608420 — intervention group
Intervention type: OTHER
Intervention: Concordance index
Description: The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
Study NCT06606015 — intervention group
Intervention type: DRUG
Intervention: I.V Paracetamol.
Description: Pharmacological thereby for hsPDA closure in the preterm neonates.
Study NCT06606015 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography.
Description: It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.
Study NCT06606015 — intervention group
Intervention type: DEVICE
Intervention: Electrical Cardiometry
Description: Non invasive hemodynamics monitoring
Study NCT05890170 — intervention group
Intervention type: OTHER
Intervention: Patient Reported Outcomes Measures
Description: Questionnaires and information extracted from the medical records would be collected.
Study NCT05772663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized program of rehabilitation
Description: D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands.
Study NCT05772663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine program of rehabilitation
Description: Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands.
Study NCT05694312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Description: Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
Study NCT04449146 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scapular positioning in Standing position using Sonography
Description: The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
Study NCT06280872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological Based Cord Clamping
Description: see Arm Description
Study NCT06280872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Differed Cord Clamping
Description: see Arm Description
Study NCT04900220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
Study NCT06347614 — intervention group
Intervention type: PROCEDURE
Intervention: Two-step Radical Prostatectomy
Description: The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
Study NCT04542772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
Study NCT04542772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
Study NCT04542772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Rehabilitation
Description: Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
Study NCT05712616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strontium Ranelate
Description: Dual mode of action, anabolic and anti-resorptive
Study NCT05712616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lacto-N-Hexaose
Description: Placebo look alike drug
Study NCT06140940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current (HD-tDCS), active condition
Description: Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
Study NCT05945043 — intervention group
Intervention type: OTHER
Intervention: Surface parasternal eletromyogram
Description: The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
Study NCT06140940 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), sham condition
Description: Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
Study NCT05945043 — intervention group
Intervention type: OTHER
Intervention: Surface diaphragm electromyogram
Description: The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal
Study NCT05945043 — intervention group
Intervention type: OTHER
Intervention: Parasternal muscle ultrasound
Description: The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal
Study NCT05945043 — intervention group
Intervention type: OTHER
Intervention: Breathlessness assessment
Description: The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
Study NCT06239376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa+AI - AC
Description: Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
Study NCT06239376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial cycle
Description: The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
Study NCT05725109 — intervention group
Intervention type: OTHER
Intervention: Hepatitis C Treatment Alerts in CHORUS™
Description: Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.
Study NCT05725109 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
Study NCT05735132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Line-blocking
Description: Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.
Study NCT05735132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bar-blocking
Description: Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.
Study NCT05735132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V-blocking
Description: Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
Study NCT05048940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Janssen vaccine
Description: 0.5 ml millilitre(s) Intramuscular use
Study NCT05048940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (Moderna) vaccine
Description: 0.5 ml millilitre(s) Intramuscular use
Study NCT04474704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheetah® non-invasive cardiac monitoring system
Description: Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))
Study NCT04474704 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: 24 hours of postpartum magnesium sulfate
Study NCT04887051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonory based home exercises
Description: web based telerehablitation
Study NCT04811625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PL-ASA
Description: Pharmacologic profile of different aspirin formulations
Study NCT04811625 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PL-ASA
Description: Pharmacologic profile of different aspirin formulations